Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 3/20 | 0.36 |
| ▸ | GCK | P35557 | 8/20 | 0.34 |
| ▸ | RAF1 | P04049 | 3/20 | 0.33 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27211501 | 1.00 | MRGPRX2 (0.43) | MRGPRX2IDO1GCKRAF1MAPK3 | |
| SCHEMBL31132457 | 1.00 | MRGPRX2 (0.43) | MRGPRX2IDO1GCKRAF1MAPK3 | |
| SCHEMBL29078026 | 0.87 | MRGPRX2 (0.55) | MRGPRX2IDO1GCKRAF1MAPK3 | |
| SCHEMBL31133294 | 0.87 | MRGPRX2 (0.55) | MRGPRX2IDO1GCKRAF1MAPK3 | |
| SCHEMBL30473701 | 0.87 | MRGPRX2 (0.55) | MRGPRX2IDO1GCKRAF1MAPK3 | |
| SCHEMBL24297738 | 0.87 | MRGPRX2 (0.55) | MRGPRX2IDO1GCKRAF1MAPK3 | |
| SCHEMBL31132482 | 0.83 | CARM1 (0.43) | MRGPRX2IDO1TDP1BRAFACACB | |
| SCHEMBL27211370 | 0.83 | MRGPRX2 (0.42) | MRGPRX2TDP1ACACB | |
| SCHEMBL29564440 | 0.83 | MRGPRX2 (0.42) | MRGPRX2TDP1ACACB | |
| SCHEMBL31510724 | 0.83 | MRGPRX2 (0.41) | MRGPRX2IDO1GCKTDP1ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4704830-A2 | MRGPRX2 INHIBITORS AND METHODS OF USE THEREOF | Septerna, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| WO-2024226914-A2 | MRGPRX2 ANTAGONISTS AND METHODS OF USE THEREOF | SEPTERNA, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| US-11976057-B2 | MrgX2 antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-05-07 | — | — | US | disclosed |
| US-20220112174-A1 | MRGX2 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11976057-B2 | MrgX2 antagonists | MRGPRX2, MRGPRX1, MRGPRX4 | MRGPRX2 1/4885IDO1 1547/4885GCK 3694/4885 |
| US-20220112174-A1 | MRGX2 ANTAGONISTS | MRGPRX2, MRGPRX1, MRGPRX4 | MRGPRX2 1/4885IDO1 1547/4885GCK 3694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.